Avanos Medical Q3 EPS Forecast Lowered by Zacks Research

Avanos Medical, Inc. (NYSE:AVNS) – Analysts at Zacks Research decreased their Q3 2025 earnings estimates for Avanos Medical in a research note issued to investors on Wednesday, March 19th. Zacks Research analyst R. Department now forecasts that the company will earn $0.30 per share for the quarter, down from their previous estimate of $0.43. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical’s FY2025 earnings at $1.20 EPS, Q2 2026 earnings at $0.30 EPS and FY2026 earnings at $1.48 EPS.

Avanos Medical (NYSE:AVNS) last announced its quarterly earnings results on Wednesday, February 26th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.40 by $0.03. The company had revenue of $179.60 million during the quarter, compared to analyst estimates of $177.23 million. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%.

Separately, StockNews.com upgraded Avanos Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, March 19th.

Avanos Medical Stock Down 1.8 %

NYSE:AVNS opened at $14.41 on Monday. Avanos Medical has a 1 year low of $14.25 and a 1 year high of $25.36. The stock has a 50-day moving average price of $15.80 and a two-hundred day moving average price of $18.58. The stock has a market cap of $662.77 million, a price-to-earnings ratio of 42.37 and a beta of 1.17. The company has a current ratio of 2.22, a quick ratio of 1.46 and a debt-to-equity ratio of 0.12.

Institutional Investors Weigh In On Avanos Medical

Several institutional investors have recently bought and sold shares of AVNS. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Avanos Medical by 10.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 120,269 shares of the company’s stock valued at $1,915,000 after purchasing an additional 11,799 shares during the last quarter. Two Sigma Investments LP increased its stake in Avanos Medical by 20.6% in the 4th quarter. Two Sigma Investments LP now owns 72,701 shares of the company’s stock valued at $1,157,000 after buying an additional 12,422 shares during the last quarter. State of Wyoming lifted its position in Avanos Medical by 132.0% during the 4th quarter. State of Wyoming now owns 5,137 shares of the company’s stock worth $82,000 after buying an additional 2,923 shares in the last quarter. ProShare Advisors LLC boosted its stake in shares of Avanos Medical by 44.4% during the 4th quarter. ProShare Advisors LLC now owns 13,693 shares of the company’s stock worth $218,000 after buying an additional 4,210 shares during the last quarter. Finally, Occudo Quantitative Strategies LP bought a new position in shares of Avanos Medical in the 4th quarter valued at about $485,000. Institutional investors own 95.17% of the company’s stock.

Insider Buying and Selling

In related news, SVP Kerr Holbrook sold 7,000 shares of the stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $15.25, for a total transaction of $106,750.00. Following the completion of the transaction, the senior vice president now directly owns 82,047 shares in the company, valued at approximately $1,251,216.75. This trade represents a 7.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.90% of the stock is currently owned by company insiders.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.